Aspargo Labs’ oral suspension products enhance patient experiences and empower physicians to manage health outcomes more effectively. Administered orally, our formulations achieve a higher absorption rate.
Our unique suspension technology optimizes the interplay between molecular particle size, coating, and viscosity, resulting in more efficient treatment delivery.
Oral suspension formulations have several advantages including accelerated absorption rates, higher bioavailability, better taste, and are often preferred by patients who have difficulty swallowing.
Aspargo Labs is at the forefront of developing a high-tech device with replaceable medication cartridges, which in the future will also be connected to a user-friendly mobile platform.
These cartridges will be available for multiple medications across various therapeutic areas, and the device will provide real time data to benefit patients, physicians and caregivers.
Oral suspension formulations have several advantages including accelerated absorption rates, higher bioavailability, better taste, and are often preferred by patients who have difficulty swallowing.
Aspargo Labs is at the forefront of developing a high-tech device with replaceable medication cartridges, which in the future will also be connected to a user-friendly mobile platform.
These cartridges will be available for multiple medications across various therapeutic areas, and the device will provide real time data to benefit patients, physicians and caregivers.
Optimizing the bioavailability of active ingredients in suspension technology for more efficient uptake
Liquid formulations reduce the complexity of dosing schedules
Allows flexibility to personalize dose regimens
Ease of administration helps patients follow doctors recommendations leading to more consistent use
Almost 40% of the population report having difficulty to swallow pills, especially for pediatric and geriatric populations
Product is currently marketed under the brand names of HEZKUE in Germany and BANDOL in Spain.
ASP-001 has also received regulatory approval in additional countries: United Kingdom, Mexico, Ireland and the Netherlands.
Aspargo Labs has completed all clinical trails to satisfy the submission of an NDA with the FDA.
Additional oral suspensions are in development for both Rx and OTC products.
Cookies are important to you because they affect your browsing experience and help protect your privacy. We use our own and third-party cookies to analyze our services and show you advertising that matches your preferences based on a profile of your browsing habits (e.g. the pages visited). If you agree to the installation of cookies, click on “Accept Cookies.” For more information, view our “Privacy Policy.”